Literature DB >> 22004909

Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome.

Kai Hang Yiu1, Nina Ajmone Marsan, Victoria Delgado, Nienke R Biermasz, Eduard R Holman, Johannes W A Smit, Richard A Feelders, Jeroen J Bax, Alberto M Pereira.   

Abstract

OBJECTIVE: Active Cushing's syndrome (CS) is associated with cardiomyopathy, characterized by myocardial structural, and ultrastructural abnormalities. The extent of myocardial fibrosis in patients with CS has not been previously evaluated. Therefore, the objective of this study was to assess myocardial fibrosis in CS patients, its relationship with left ventricular (LV) hypertrophy and function, and its reversibility after surgical treatment. DESIGN AND METHODS: Fifteen consecutive CS patients (41±12 years) were studied together with 30 hypertensive (HT) patients (matched for LV hypertrophy) and 30 healthy subjects. Echocardiography was performed in all patients including i) LV systolic function assessment by conventional measures and by speckle tracking-derived global longitudinal strain, ii) LV diastolic function assessment using E/E', and iii) myocardial fibrosis assessment using calibrated integrated backscatter (IBS). Echocardiography was repeated after normalization of cortisol secretion (14±3 months).
RESULTS: CS patients showed the highest value of calibrated IBS (-15.1±2.5  dB) compared with HT patients (-20.0±2.6  dB, P<0.01) and controls (-23.8±2.4  dB, P<0.01), indicating increased myocardial fibrosis independent of LV hypertrophy. Moreover, calibrated IBS in CS patients was significantly related to both diastolic function (E/E', r=0.79, P<0.01) and systolic function (global longitudinal strain, r=0.60, P=0.02). After successful surgical treatment, calibrated IBS normalized (-21.0±3.8 vs -15.1±2.5  dB, P<0.01), suggestive of regression of myocardial fibrosis.
CONCLUSIONS: Patients with CS have increased myocardial fibrosis, which is related to LV systolic and diastolic dysfunction. Successful treatment of CS normalizes the extent of myocardial fibrosis. Therefore, myocardial fibrosis appears to be an important factor in the development and potential regression of CS cardiomyopathy.

Entities:  

Mesh:

Year:  2011        PMID: 22004909     DOI: 10.1530/EJE-11-0601

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  21 in total

1.  Cardiac hypertrophy in Cushing's syndrome: if not hypertension then what?

Authors:  D A Vassiliadi; S Tsagarakis
Journal:  Endocrine       Date:  2017-02-17       Impact factor: 3.633

2.  Left ventricular geometry and 24-h blood pressure profile in Cushing's syndrome.

Authors:  Eleonora Avenatti; Andrea Rebellato; Andrea Iannaccone; Marialberta Battocchio; Francesca Dassie; Franco Veglio; Alberto Milan; Francesco Fallo
Journal:  Endocrine       Date:  2016-05-14       Impact factor: 3.633

Review 3.  Clinical and biochemical manifestations of Cushing's.

Authors:  Georgia Ntali; Ashley Grossman; Niki Karavitaki
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 4.  Hypercortisolism in obesity-associated hypertension.

Authors:  Amy G Varughese; Oksana Nimkevych; Gabriel I Uwaifo
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

5.  Coronary microvascular function in patients with Cushing's syndrome.

Authors:  Francesco Fallo; Giulia Famoso; Dario Capizzi; Nicoletta Sonino; Francesca Dassie; Pietro Maffei; Chiara Martini; Agostino Paoletta; Sabino Iliceto; Francesco Tona
Journal:  Endocrine       Date:  2012-08-01       Impact factor: 3.633

6.  Assessment of left ventricular function by two-dimensional speckle-tracking echocardiography in small breed dogs with hyperadrenocorticism.

Authors:  Hung-Yin Chen; Yu-Hsin Lien; Hui-Pi Huang
Journal:  Acta Vet Scand       Date:  2014-12-31       Impact factor: 1.695

Review 7.  The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications.

Authors:  Andrea M Isidori; Chiara Graziadio; Rosa Maria Paragliola; Alessia Cozzolino; Alberto G Ambrogio; Annamaria Colao; Salvatore M Corsello; Rosario Pivonello
Journal:  J Hypertens       Date:  2015-01       Impact factor: 4.844

8.  Reversible alterations in cardiac morphology and functions in a patient with Cushing's syndrome.

Authors:  Hiroaki Iwasaki
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-06-01

9.  Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study.

Authors:  Peter Kamenický; Alban Redheuil; Charles Roux; Sylvie Salenave; Nadjia Kachenoura; Zainab Raissouni; Laurent Macron; Laurence Guignat; Christel Jublanc; Arshid Azarine; Sylvie Brailly; Jacques Young; Elie Mousseaux; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2014-08-05       Impact factor: 5.958

10.  Cushing Syndrome Associated Myopathy: It Is Time for a Change.

Authors:  Martin Reincke
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.